Showing 261 - 280 results of 675 for search '"combination therapy"', query time: 0.06s Refine Results
  1. 261

    The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination by Graham Skelhorne-Gross, Christopher J. B. Nicol

    Published 2012-01-01
    “…There are many examples in which combination therapy resulted in synergistic/additive effects on apoptosis, differentiation, and the ability to reduce cell growth and tumour burden. …”
    Get full text
    Article
  2. 262

    Successful Treatment of High-Level Aminoglycoside-Resistant Enterococcus faecalis Bacteremia in a Preterm Infant with Ampicillin and Cefotaxime by Jennifer Tam, Santina J. Lee, Vibhuti Shah, Shaun K. Morris

    Published 2018-01-01
    “…In persistent infections, synergistic combination therapy is often required with a beta-lactam and an aminoglycoside antibiotic. …”
    Get full text
    Article
  3. 263

    Modulating lipid metabolism improves tumor immunotherapy by Yi Zhang, Yu Ping, Qiuqing Fan

    Published 2025-02-01
    “…Consequently, lipid metabolism emerges as an important immune regulator for improving immunotherapeutic outcomes and provides a novel and powerful strategy for tumor combination therapy.…”
    Get full text
    Article
  4. 264

    Rare Form of Erdheim-Chester Disease Presenting with Isolated Central Skeletal Lesions Treated with a Combination of Alfa-Interferon and Zoledronic Acid by E. N. Bulycheva, V. V. Baykov, M. I. Zaraĭskiĭ, G. N. Salogub

    Published 2015-01-01
    “…Here, we present a case report of a young male patient with isolated lesions of the spine, ribs, and pelvis, who was successfully treated with a combination therapy of alfa-interferon and zoledronic acid.…”
    Get full text
    Article
  5. 265

    A review on the potential of Bruton’s tyrosine kinase (Btk) inhibitor – Ibrutinib for treatment of Multiple Myeloma (MM) by Sze-Ting Bong, Lydia Ngiik-Shiew Law, Jodi Woan-Fei Law

    Published 2019-05-01
    “…To date, clinical trials of ibrutinib as therapeutic alternative for MM have produced promising results, particularly as combination therapy with other agents such as dexamethasone and carfilzomib. …”
    Get full text
    Article
  6. 266

    Impact of Retinoic Acid on Immune Cells and Inflammatory Diseases by Luana de Mendonça Oliveira, Franciane Mouradian Emidio Teixeira, Maria Notomi Sato

    Published 2018-01-01
    “…The mechanism of RA is interesting to explore as both a mucosal adjuvant and a combination therapy with other effective agents. Here, we review the effect of RA on innate and adaptive immunity with a special emphasis on inflammatory status.…”
    Get full text
    Article
  7. 267

    PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands by Vasudha Mishra, Alka Singh, Michael Korzinkin, Xiangying Cheng, Claudia Wing, Viktoria Sarkisova, Ashwin L. Koppayi, Alexandra Pogorelskaya, Oksana Glushchenko, Manu Sundaresan, Venkat Thodima, Jack Carter, Koichi Ito, Peggy Scherle, Anna Trzcinska, Ivan Ozerov, Everett E. Vokes, Grayson Cole, Frank W. Pun, Le Shen, Yuxuan Miao, Alexander T. Pearson, Mark W. Lingen, Bruce Ruggeri, Ari J. Rosenberg, Alex Zhavoronkov, Nishant Agrawal, Evgeny Izumchenko

    Published 2025-01-01
    “…Molecular changes associated with response to PRMT5 inhibition and anti-proliferative effect of the combination therapy with lenvatinib was then analyzed. Results Using a comprehensive AI-powered engine for target identification, PRMT5 was predicted among potential therapeutic target candidates for ACC. …”
    Get full text
    Article
  8. 268

    Iodine-131 Metaiodobenzylguanidine Therapy for Neuroblastoma: Reports So Far and Future Perspective by Daiki Kayano, Seigo Kinuya

    Published 2015-01-01
    “…In contrast, more than 12 mCi/kg I-131 MIBG administrations with or without hematopoietic cell transplantation (HCT) obtain relatively good responses in patients with refractory or relapsed neuroblastoma. The combination therapy with I-131 MIBG and other modalities such as nonmyeloablative chemotherapy and myeloablative chemotherapy with HCT improved the therapeutic response in patients with refractory or relapsed neuroblastoma. …”
    Get full text
    Article
  9. 269

    Combination Treatment of C16 Peptide and Angiopoietin-1 Alleviates Neuromyelitis Optica in an Experimental Model by Yuanyuan Zhang, Kewei Tian, Hong Jiang, Beibei Wang, Shu Han

    Published 2018-01-01
    “…Our results demonstrated that this combination therapy significantly decreased disease severity, inflammatory cell infiltration, secondary demyelination, and axonal loss, thus reducing neural death. …”
    Get full text
    Article
  10. 270

    Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs by Xing Wan, Jingyuan Ma, He Bai, Xuyang Hu, Yanna Ma, Mingjian Zhao, Jifeng Liu, Zhijun Duan

    Published 2025-01-01
    “…This review summarizes the recent advances in the treatment of NAFLD, focusing on the mechanisms of action of natural products, small-synthetic-molecule drugs, and combination therapy strategies. This review aims to provide new insights and strategies in treating NAFLD.…”
    Get full text
    Article
  11. 271

    Icariin Promotes Survival, Proliferation, and Differentiation of Neural Stem Cells In Vitro and in a Rat Model of Alzheimer’s Disease by Denglei Ma, Lihong Zhao, Li Zhang, Yali Li, Lan Zhang, Lin Li

    Published 2021-01-01
    “…These results suggest that combination therapy of ICA oral administration and NSC transplantation may provide a new potential and effective approach for AD therapy.…”
    Get full text
    Article
  12. 272

    Cutaneous Metastases of the Synchronous Primary Endometrial and Bilateral Ovarian Cancer: An Infrequent Presentation and Literature Review by Gul Kanyilmaz, Meryem Aktan, Mehmet Koc, Siddika Findik

    Published 2016-01-01
    “…The patient received the combination therapy with cisplatin and doxorubicin after the completion of radiotherapy but the disease evolution was rapidly fatal and the patient died 4 months after her admission to our department due to widely disseminated disease.…”
    Get full text
    Article
  13. 273

    Hepatoprotector in cases of dengue hemorrhagic fever as a prevention of hepatic damage: a case report by Emilia Gan, Yenry Sumarlim, Desantika Wuryana, M. Hari Pristantiningtyas, Herya Putra Dharma, Muhammad Muchlis, Jainuri Erik Pratama, Adji Prayitno Setiadi, Marisca Evalina Gondokesumo

    Published 2023-07-01
    “…To prevent worsening liver damage, combination therapy with Ursodeoxycholic Acid (UDCA) and curcumin was given as a hepatoprotector. …”
    Get full text
    Article
  14. 274

    Pharmacotherapy of Peptic Ulcer Disease by F Molina, MM Vohra, CN Williams

    Published 1991-01-01
    “…Mucosal protectives (or ‘cytoprotectives’) as a group seem to have a lower relapse rate than the H2 receptor antagonists at one year. Combination therapy has not yet proved to be better than single drug therapy; however, the number of studies is still small, and more clinical trials are necessary. …”
    Get full text
    Article
  15. 275

    From detection to elimination: iron-based nanomaterials driving tumor imaging and advanced therapies by Dong Xie, Linglin Sun, Manxiang Wu, Qiang Li

    Published 2025-02-01
    “…Regarding treatment, INMs play a key role in advanced strategies such as immunotherapy, magnetic hyperthermia, and synergistic combination therapy, which effectively overcome tumor-induced drug resistance and reduce systemic toxicity. …”
    Get full text
    Article
  16. 276

    Granulomatous dermatitis post Mycobacterium Indicus Pranii (MIP) vaccine in severe covid-19 infection: an exaggerated hypersensitivity phenomenon by Pooja Agarwal, Raju Chaudhary, Kalgi Baxi, Malhar Shah

    Published 2024-01-01
    “…The patient was started on a combination therapy of ofloxacin 400 mg /day and clarithromycin 500 mg 12 hourly for 2 months. …”
    Get full text
    Article
  17. 277

    Imatinib-resistance without BCR/ABL Point Mutation in Chronic Myeloid Leukemia by Aytan Shirinova

    Published 2024-03-01
    “…In the future, new molecules for BCR-ABL inhibitors, combination therapy, and molecules entering the blood-brain barrier may improve the outcomes of therapy and prevent imatinib resistance in CML.…”
    Get full text
    Article
  18. 278

    Th1 Cytokine-Secreting Recombinant Mycobacterium bovis Bacillus Calmette-Guérin and Prospective Use in Immunotherapy of Bladder Cancer by Yi Luo, Jonathan Henning, Michael A. O'Donnell

    Published 2011-01-01
    “…., interferon-α) has demonstrated improved efficacy, combination therapy requires multiple applications and a large quantity of cytokines. …”
    Get full text
    Article
  19. 279

    Fatal Case of Probable Invasive Aspergillosis after Five Years of Heart Transplant: A Case Report and Review of the Literature by Toufik Mahfood Haddad, Mahesh Anantha Narayanan, Krista E. Shaw, Renuga Vivekanandan

    Published 2015-01-01
    “…Bronchoalveolar lavage (BAL) was performed as her respiratory status worsened and voriconazole was added for possible aspergillosis in combination therapy with micafungin. BAL galactomannan returned positive which was suggestive of aspergillosis. …”
    Get full text
    Article
  20. 280

    Interferon-gamma: A Potent Antiviral Agent Targeting Macrophages Infected with LP-BM5 Murine Leukemia Virus, the Causative Agent of 'AIDS' in Mice by Jens J Kort, Julie L Eiseman

    Published 1992-01-01
    “…Further, since a lower concentration of each agent was required for efficacy in combination therapy, toxicity associated with single agent therapy may be avoided.…”
    Get full text
    Article